Pivonello, R. http://orcid.org/0000-0002-9632-1348
Pivonello, C.
Simeoli, C.
De Martino, M. C.
Colao, A.
Article History
Received: 2 February 2020
Accepted: 6 August 2021
First Online: 23 April 2022
Declarations
:
: R.P. has been Principal Investigator of Clinical and/or Translational Research Studies for Novartis, HRA Pharma, Ipsen, Shire, Corcept Therapeutics, Cortendo AB-Strongbridge Biopharma, Janssen Cilag, Camurus and Pfizer; Co-investigator of Research Studies for Pfizer; received research grants from Novartis, Pfizer, Ipsen, HRA Pharma, Shire, IBSA, Strongbridge Biopharma; has been an occasional consultant for Novartis, Ipsen, Pfizer, Shire, HRA Pharma, Cortendo AB-Strongbridge Biopharma, Ferring, Recordati Rare Disease, Corcept Therapeutics, Crinetics Pharmaceuticals, ARH Healthcare, Biohealth Italia, Damor Farmaceutici; and has received fees and honoraria for presentations from Novartis, Shire, Pfizer and Recordati beyond the confines of this work. C.P. received research grants from Corcept Therapeutics. C.S. has been occasional consultant for Shire and Ipsen. A.C. has been Principal Investigator of Research Studies for Novartis, Ipsen, Pfizer, Lilly, Merck and Novo Nordisk; consultant for Novartis, Ipsen, Pfizer, and received honoraria from Novartis, Ipsen and Pfizer beyond the confines of this work. M.C.D.M. has nothing to disclose.
: This article does not contain any human participants and/or animals performed by any of the authors.
: For this type of study formal consent is not required.